CELL INTELLIGENCE · 肿瘤细胞治疗研究

下一代基于抗体的癌症治疗：抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用

Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors

Mosunetuzumab 联合 polatuzumab vedotin 治疗 BTK 抑制剂治疗后的复发/难治性 MCL：一项 2 期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

短程递增给药 glofitamab 使弥漫大 B 细胞淋巴瘤患者抗 CD19 CAR-T 细胞治疗失败后死亡风险减半：LYSA BiCAR 预设外部对照臂 II 期试验最终结果

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final result

复发/难治性 B 细胞非霍奇金淋巴瘤中 CD19/20 CAR-T 疗法的临床结局与空间转录组图谱

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma.

双特异性 CD19/20 CAR-T 疗法产生了持久的临床活性，且毒性可控。

难治性特发性炎性肌病相关间质性肺疾病的新型治疗策略

Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease.

AI 引导的 CAR 设计与靶向通路调控以增强多抗原 CAR-T 细胞持久性并克服抗原逃逸

AI-guided CAR designs and targeted pathway modulation to enhance multi-antigen CAR T cell durability and overcome antigen escape.

系统综述与荟萃分析：CAR-T 对比双特异性抗体作为滤泡性淋巴瘤三线及后线治疗

Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.

CD3 细胞治疗用于非霍奇金淋巴瘤：I/II 期临床试验（Institute of Hematology）

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-c

这是一项 I/II 期注册临床试验，评估细胞治疗用于非霍奇金淋巴瘤的疗效与安全性。当前状态：进行中（不再招募）。计划入组 53 例。试验地点：中国 · 天津（共 1 个中心，其中中国 1 个）。登记号：NCT06464185。

疗效-安全性权衡与患者选择：一项为 R/R B-NHL 中 CAR-T 与双特异性抗体临床选择提供依据的 meta 分析

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL.

真实世界中接受 epcoritamab 或 glofitamab 治疗的侵袭性 B 细胞淋巴瘤患者的结局

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.